Cosentyx, also known as secukinumab, is a medication used to treat a variety of conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It is a type of drug called a monoclonal antibody, which works by targeting and blocking a specific protein in the body that is involved in inflammation [1].
According to the drug's manufacturer, Novartis, there is limited information available on the impact of Cosentyx on the immune system's response to vaccines [2]. However, they do recommend that patients complete their vaccine schedule before starting Cosentyx, if possible [2]. It is also recommended that live vaccines be avoided while on Cosentyx, as the drug may affect the body's ability to respond to the vaccine [2].
A study published in the Journal of the American Academy of Dermatology found that patients with psoriasis who were treated with biologic drugs, such as Cosentyx, had a reduced immune response to the influenza vaccine compared to those not on biologic therapy [3].
In summary, it is unclear how Cosentyx may affect a person's response to vaccines, but it is recommended that patients complete their vaccine schedule before starting the drug and avoid live vaccines while on Cosentyx [2]. Additionally, a study has shown that patients on biologic therapy, such as Cosentyx, may have a reduced immune response to the influenza vaccine [3].
Sources:
1. Mayo Clinic. Cosentyx (secukinumab). <https://www.mayoclinic.org/drugs-supplements/cosentyx-secukinumab-subcutaneous-route/description/drg-20273652>.
2. Novartis. Cosentyx (secukinumab) injection, for subcutaneous use. <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyx.pdf>.
3. Gottlieb AB, et al. Influenza Vaccination in Patients With Psoriasis Receiving Biologic Therapy. J Am Acad Dermatol. 2016;75(3):555-561.e1. doi:10.1016/j.jaad.2016.05.033. <https://www.jaad.org/article/S0190-9622(16)30831-3/fulltext>.
4. DrugPatentWatch.com. Secukinumab. <https://www.drugpatentwatch.com/drugs/secukinumab>.